Wilson Sonsini Goodrich & Rosati advised Verve on IP matters related to the transaction. Verve Therapeutics, Inc., a clinical-stage genetic medicines company, announced an exclusive research collaboration...
Verve Therapeutics’ Collaboration Agreement with Lilly
Chroma Medicine’s $135 Million Series B Financing
Wilson Sonsini advised Chroma Medicine on the deal. Genomic medicine company Chroma Medicine announced that it had completed a $135 million Series B financing, which was...
Marengo Therapeutics’ Partnership with Ipsen
Wilson Sonsini Goodrich & Rosati advised Marengo on the deal. Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated...
Verve Therapeutics’ $225 Million Shares Public Offering
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease...
NAPIGEN’s $7.85 Million Seed Financing
Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...
Galapagos’ Acquisition of CellPoint
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
Chroma Medicine’s $125 Million Financing
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
Verve Therapeutics’ $306 Million IPO
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...